InVitria Achieves cGMP Qualification Milestone
News Feb 11, 2011
InVitria announces that its Lysobac cell lysing reagent is manufactured at the Company’s Junction City, Kansas facility under cGMP (Current Good Manufacturing Practice) standards. Lysobac is a completely animal component free reagent that is substantially more effective and consistent than hen egg white lysozyme and complies with global regulatory standards for manufacturing biotherapeutics.
“Achievement of this milestone demonstrates InVitria’s commitment to the high quality standards that our customers expect,” said Shawn Smith, Vice President of Sales & Marketing.
“Customers routinely inspect our facility and operations as part of their normal purchasing and vendor qualification process. With the introduction of cGMP-grade Lysobac, we are raising the bar for the quality of reagents used in biomanufacturing,” said Greg Unruh, Vice President of Manufacturing.
InVitria’s Lysobac is used in the manufacture of several products derived from microbial fermentation such as E. coli. Lysobac is more than four times more effective than hen egg white lysozyme and because it is derived from recombinant production, it is delivers consistent performance. For more information about Lysobac, please visit www.Lysobac.com.
All biomanufacturing products from InVitria are animal component free and manufactured in Kansas. They include cell culture media supplements that optimize performance of cell lines including CHO, hybridoma, Vero, MDCK, mesenchymal, pluripotent, keratinocyte, chondrocyte and a wide array of stem and primary cell lines.
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019
10th International Tissue Repair and Regeneration Congress
Jun 13 - Jun 14, 2019
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
International Conference on Hepatology and Liver Diseases
Jun 10 - Jun 11, 2019